Breaking News, Collaborations & Alliances

Saiba AG and AGC Biologics Enter COVID-19 Vaccine Partnership

AGC will manufacture SARS-CoV-2 vaccine for the Swiss biotech

By: Contract Pharma

Contract Pharma Staff

AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), is partnering with Saiba AG to manufacture a SARS-CoV-2 vaccine to protect against COVID-19. Saiba AG is a Swiss biotechnology company that specializes in the research and development of virus-like particle (VLP) vaccines for infectious and chronic diseases. Saiba AG is leveraging its patented Cucumber Mosaic Virus VLP platform technology to develop the SARS-CoV-2 vaccine.   The recombinant subu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters